Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

norbrook laboratories (ireland) limited -

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa - dirlotapid - preparati za zaščito proti sončenju, prehrambeni izdelki - psi - kot pomoč pri obvladovanju prekomerne telesne teže in debelosti pri odraslih psih. uporablja se kot del splošnega programa za upravljanje telesne teže, ki vključuje tudi ustrezne prehranske spremembe in prakso vadbe.

Evropska unija - slovenščina - EMA (European Medicines Agency)

teva b.v. - colistimethate natrijev - cistična fibroza - antibacterials za sistemsko uporabo, - colobreathe je navedeno za upravljanje kronične pljučne okužbe zaradi pseudomonas aeruginosa pri bolnikih s cistično fibrozo (cf), starih šest let in starejši. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Evropska unija - slovenščina - EMA (European Medicines Agency)

teva b.v. - clopidogrel (as hydrogen sulfate) - myocardial infarction; acute coronary syndrome; peripheral vascular diseases; stroke - antitrombotična sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. za odrasle bolnike, ki trpijo za akutni koronarni sindrom:non-st segmentu višinskih akutni koronarni sindrom (nestabilna angina pektoris ali ne-q-val, miokardni infarkt), vključno z bolniki, ki opravljajo stent umestitev po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilne kisline (asa). st segmentu višinskih akutni miokardni infarkt, v kombinaciji s asa v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija. preprečevanje atherothrombotic in thromboembolic dogodkov v atrijska fibrillationin odraslih bolnikov z atrijsko fibrilacijo, ki imajo vsaj en dejavnik tveganja za žilne dogodke, niso primerni za zdravljenje z antagonisti vitamina k (vka) in ki imajo nizko tveganje krvavitve, clopidogrel je indiciran v kombinaciji s asa za preprečevanje atherothrombotic in thromboembolic dogodkov, vključno z možgansko kap.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zoetis belgium sa - toceranib - antineoplastična sredstva - psi - zdravljenje nerazprtega zdravila patnaik razred-ii (vmesni razred) ali -iii (visokokakovostnih), ponavljajočih, tumorjev tumorja mastocitov pri psih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - isoxazolines, ectoparasiticides za sistemsko zdravljenje - psi - zdravljenje bolh okužbe pri psih (ctenocephalides felis in c. canis) za vsaj 5 tednov. izdelek se lahko uporablja kot del strategije zdravljenja za nadzor alergijskega dermatitisa bolha (fad). zdravljenje klopi okužbe pri psih (dermacentor reticulatus, ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus). eno zdravljenje ubija klopi za največ en mesec. bolhe in klopi mora priložiti gostiteljice in začne hranjenje, da bi izpostavljene aktivni snovi,. zdravljenje demodicosis (zaradi demodex canis). zdravljenje sarcoptic mange (zaradi sarcoptes scabiei var. canis).

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - ektoparaziticidi za sistemsko uporabo - psi - zdravljenje bolh (ctenocephalides felis in c. canis) infestations. izdelek se lahko uporablja kot del strategije zdravljenja za nadzor alergijskega dermatitisa bolha (fad). zdravljenje klopi (dermacentor reticulatus, ixodes ricinus, rhipicephalus sanguineus) infestations. zdravljenje demodicosis (zaradi demodex canis). zdravljenje sarcoptic mange (zaradi sarcoptes scabiei var. canis).

Evropska unija - slovenščina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

dechra regulatory b.v. - maropitant - zdravljene bolezni prebavil in presnove, druge antiemetics - cats; dogs - psi:za preprečevanje in zdravljenje slabosti, ki jih chemotherapyfor preprečevanje bruhanja, razen, ki povzročijo gibanja sicknessfor zdravljenje bruhanje, v kombinaciji z drugimi spodbudno measuresfor preprečevanje perioperative slabost in bruhanje in izboljšanje predelave iz splošne anestezije, po uporabi μ-opiatov je agonist receptorjev morphinecats:za preprečevanje bruhanja in zmanjšanje slabost, razen, ki povzročijo gibanja sicknessfor zdravljenje bruhanje, v kombinaciji z drugimi podpornimi ukrepi.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bioveta -